LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Biogen Inc

Затворен

СекторЗдравеопазване

140.29 0.24

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

140.04

Максимум

141.94

Ключови измерители

By Trading Economics

Приходи

394M

635M

Продажби

215M

2.6B

P/E

Средно за сектора

12.653

35.733

EPS

3.02

Марж на печалбата

23.995

Служители

7,605

EBITDA

457M

1B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+20.72% upside

Дивиденти

By Dow Jones

Следващи печалби

29.10.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

442M

19B

Предишно отваряне

140.05

Предишно затваряне

140.29

Настроения в новините

By Acuity

31%

69%

92 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

Biogen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.09.2025 г., 09:30 ч. UTC

Придобивния, сливания и поглъщания

Armani Stuck to the Classics. But His Business Needs a Refresh -- Heard on the Street -- WSJ

6.09.2025 г., 08:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

5.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

5.09.2025 г., 20:37 ч. UTC

Придобивния, сливания и поглъщания

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

5.09.2025 г., 20:37 ч. UTC

Придобивния, сливания и поглъщания

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

5.09.2025 г., 20:36 ч. UTC

Придобивния, сливания и поглъщания

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

5.09.2025 г., 20:36 ч. UTC

Придобивния, сливания и поглъщания

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

5.09.2025 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

5.09.2025 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

5.09.2025 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

5.09.2025 г., 20:20 ч. UTC

Печалби

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5.09.2025 г., 19:23 ч. UTC

Пазарно говорене

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

5.09.2025 г., 19:22 ч. UTC

Печалби

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

5.09.2025 г., 19:17 ч. UTC

Пазарно говорене

U.S. Natural Gas Snaps Winning Streak -- Market Talk

5.09.2025 г., 18:59 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5.09.2025 г., 18:35 ч. UTC

Пазарно говорене

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

5.09.2025 г., 17:25 ч. UTC

Пазарно говорене

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

5.09.2025 г., 17:20 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

5.09.2025 г., 17:17 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

5.09.2025 г., 17:17 ч. UTC

Пазарно говорене

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

5.09.2025 г., 17:03 ч. UTC

Пазарно говорене

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

5.09.2025 г., 16:39 ч. UTC

Придобивния, сливания и поглъщания

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

5.09.2025 г., 16:39 ч. UTC

Придобивния, сливания и поглъщания

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

5.09.2025 г., 16:39 ч. UTC

Придобивния, сливания и поглъщания

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

5.09.2025 г., 16:39 ч. UTC

Придобивния, сливания и поглъщания

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

5.09.2025 г., 16:37 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Global Equities Roundup: Market Talk

5.09.2025 г., 16:37 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Global Energy Roundup: Market Talk

5.09.2025 г., 16:37 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

5.09.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

5.09.2025 г., 16:16 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Biogen Inc Прогноза

Ценова цел

By TipRanks

20.72% нагоре

12-месечна прогноза

Среден 169.81 USD  20.72%

Висок 260 USD

Нисък 118 USD

Според 26 анализатори от Wall Street, предложили 12-месечна ценова цел за Biogen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

26 ratings

12

Купи

14

Задържане

0

Продай

Техническа оценка

By Trading Central

118.15 / 121.17Подкрепа & съпротива

Краткосрочен план

Weak Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

92 / 371 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat